The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitorDuring the last two decades, the landscape for psoriasis treatment has exploded. The advent of biologic therapies at Share XThe key to psoriasis innovation? Dispelling the shadow of the JAK inhibitorhttps://pharmaphorum.com/partner-content/the-key-to-psoriasis-innovation-dispelling-the-shadow-of-the-jak-inhibitor/
Almirall kicks off another hunt for skin disease therapy partnershipsSpanish drugmaker Almirall has launched another search for early-stage research projects that it can partner in dermatology, its Share XAlmirall kicks off another hunt for skin disease therapy partnershipshttps://pharmaphorum.com/news/almirall-kicks-off-another-hunt-for-skin-disease-therapy-partnerships/
Dermavant raises $200m to ease launch of Otezla rival tapinarofDermavant is in line to make some big payments to GlaxoSmithKline if its topical psoriasis drug tapinarof reaches Share XDermavant raises $200m to ease launch of Otezla rival tapinarofhttps://pharmaphorum.com/news/dermavant-raises-200m-to-ease-launch-of-otezla-rival-tapinarof/
Amgen pays Kyowa $400m upfront for OX40 eczema drugAmgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim Share XAmgen pays Kyowa $400m upfront for OX40 eczema drughttps://pharmaphorum.com/news/amgen-pays-kyowa-400m-upfront-for-ox40-eczema-drug/
Incyte preps second filing for ruxolitinib cream after vitiligo trial winIncyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can Share XIncyte preps second filing for ruxolitinib cream after vitiligo trial winhttps://pharmaphorum.com/news/incyte-preps-second-filing-for-ruxolitinib-cream-after-vitiligo-trial-win/
Crowded psoriasis market cuts Lilly’s mirikizumab ambitionsEli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file Share XCrowded psoriasis market cuts Lilly’s mirikizumab ambitionshttps://pharmaphorum.com/news/crowded-psoriasis-market-cuts-lillys-mirikizumab-ambitions/
Avillion/Merck psoriasis nanobody hits the mark in phase 2UK biotech Avillion has reported positive mid-stage results with chronic psoriasis drug sonelokimab, which it is developing with Share XAvillion/Merck psoriasis nanobody hits the mark in phase 2https://pharmaphorum.com/news/avillion-merck-psoriasis-nanobody-hits-the-mark-in-phase-2/
Lilly’s Olumiant is first JAK drug backed by NICE for eczemaEli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended Share XLilly’s Olumiant is first JAK drug backed by NICE for eczemahttps://pharmaphorum.com/news/lillys-olumiant-is-first-jak-drug-backed-by-nice-for-eczema/
Almirall names Nazzi as new CEO after Guenter leaves for MerckSpanish drugmaker Almirall has lined up its new CEO following the departure of Peter Guenter, who left to Share XAlmirall names Nazzi as new CEO after Guenter leaves for Merckhttps://pharmaphorum.com/news/almirall-names-nazzi-as-new-ceo-after-guenter-leaves-for-merck/
